Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)
Authors
von Moos, RHawle, H
Hayoz, S
Cathomas, R
Muller, A
Schmid, S
Pagani, O
Wehrhahn, T
Rauch, D
Anchisi, S
Hermanns, T
Fehr, M
Stoll, S
Butzberger, P
Zweifel, M
Huber, U
Fuhrer, AC
Schar, C
Gillessen, Silke
Templeton, AJ
Affiliation
Department of Oncology/Hematology, Kantonsspital Graub�nden, Chur, SwitzerlandIssue Date
2018
Metadata
Show full item recordCitation
von Moos R, Hawle H, Hayoz S, Cathomas R, M�ller A, Schmid S, et al. 1703P Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy300.020PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy300.020Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy300.020